中国临床药学杂志

参考文献

[1]Mackenziea PI,Bock KW,Burchell B,et al.Nomenclature update for the mammalian UDP glycosyhransferase(UGT)gene superfamily[J].Pharmacogenet Genomics,2005,15(10):677.

[2]Miyagi SJ,Collier AC.Pediatric development of glucuronidation:the ontogeny of hepatic UGT1A4[J].Drug Metab Dispos,2007,35(9): 1587.

[3]和凡.拉莫三嗪药代动力学及儿科临床应用的进展[J].儿科药学杂志,2010,16(4):55.

[4]Sun DX,Chen G.Dellinger RW,et al.Characterization of tamoxifen and 4-hydroxy tamoxifen glucuronidation by human UGT1A4 variants[J]. Breast Cancer Res,2006,8(4):R50.

[5]周娟,周宏灏.UGT1A基因的遗传多态性对底物代谢的影响[J].生物科学进展,2007,38(3):235.

[6]郭栋,庞良芳,周宏灏.尿苷二磷酸葡萄糖醛酸基转移酶基因多态性的研究进展[J].生物科学进展,2010,41(2):107.

[7]Ehmer U,Vogel A,Schutte JK,et al.Variation of hepatic glucuronida- tion:novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4[J].Hepatology,2004,39(4):970.

[8]Mori A,Maruo Y,Iwai M,et al.UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinefics of clozapine[J].Drug Metab Dispos,2005,33(5):672.

[9]Menard V,Girard H,Harvey M,et al.Analysis of inherited genetic variations at the UCT1 locus in the French-Canadian population[J]. Hum Mutat,2009,30(4):677.

[10]Benoit-Biancamano MO,Adam JP,Bernard O,et al.A pharmacogenetics study of the human glucuronosyl transferase UGT1A4[J].Pharmacogenet Genomics,2009,19(12):945.

[11]Gulcbi MI,Ozkaynakci A,Goren MZ,et al.Plasma lamotrigine levels of patients with poly- morphic UGT1A4 enzymes[J].Epilepsia,2010,51 (Supp4):69.

[13]Duchowny M,Pellock JM,Graf WD,et al.A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children[J].Neurology, 1999,53(8):1724.

[13]Valencia I,Pinol-Ripoll G,Khurana DS,et al.Efficacy and safety of lamotrigine mono- therapy in children and adolescents with epilepsy [J].Eur J Paediatr Neuro,2009,13(2):141.

[14]Zubcevic S,Cengic A,Catibusic F,et al.Use of lamotrigine in medically intractable epilepsies in children[J].Med Arh,2008,62(3): 162.

[15]Goa KL,Ross SR,Chrisp P.Lamotrigine——a review of its pharmacological properties and clinical efficacy in epilepsy[J].Drugs,1993, 46(1):152.

[16]张坤,王丽,卢炜.癫痫儿童拉莫三嗪的群体药动学研究[J].中国当代儿科杂志,2008,10(2):105.

[17]Rowland A,Elliot DJ,Williams JA,et al.In atro characterization of lamotrigine N2-ghcuronidation and the lamotrigine-valproic acid interaction [J].Drug Metab Dispos,2006,34(6):1055.

[18]Pennell PB,Newport DJ,Stowe ZN,et al.The impact of pregnancy and childbirth on the metabolism of lamotrigine[J].Neurology,2004,62 (2):292.

[19]Sanchez MB,Henanz JL,Leno C,et al.UGT2B7-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study on the metabolism of lamotrigine[J].Ther Drug Monit,2010,32(2):177.

[20]Ohman I,Beck O,Vitols S,et al.Plasma concentrations of lamotrigine and its 2-N-glucur- onide metabolite during pregnancy in women with epilepsy[J].Epilepsia,2008,49(6):1075.

[21]刘颖,王丽.群体药代动力学在儿童药物治疗中的应用[J].儿科药学杂志,2008,14(3):4.

[22]Grasela TH,Fiedler-Kelly J,Cox E,et al.Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy[J].J Clin Pharmacol,1991,39(4):373.

[23]Chen C.Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children[J].Brit J Clin Pharmaco,2000,50 (2):135.

[24]Erickson-Ridout KK,Zhu JJ,Lazarus P.Olanzapine metabolism and the significance of UGT1A4(48V) and UGT2B10(67Y) variants[J]. Pharmacogenet Genomics,2011,21(9):539.

[25]Ghotbi R,Mannheimer B,Aklillu E,et al.Carriers of the UCT1A4 142T > G gene variant are predisposed to reduced olanzapine exposurean impact similar to male gender or smoking in schizophrenic patients [J].Eur J Clin Pharmacol,2010,66(5):465.